Siltuximab (CNTO 328): a promising option for human malignancies

Drug Des Devel Ther. 2015 Jul 2;9:3455-8. doi: 10.2147/DDDT.S86438. eCollection 2015.

Abstract

Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of siltuximab in the treatment of human malignancies. We also provide our recommendations for siltuximab treatment in the future.

Keywords: Castleman’s disease; clinical trials; interleukin-6.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Interleukin-6 / antagonists & inhibitors*
  • Interleukin-6 / immunology
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neoplasms / pathology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • IL6 protein, human
  • Interleukin-6
  • siltuximab